The COVID-19 pandemic transformed RNA technologies into one of the most visible scientific breakthroughs of the decade. mRNA vaccines demonstrated unprecedented speed of development, large-scale manufacturing capability and global deployment, pushing RNA therapeutics into the public spotlight. But according to companies working in the field, the pandemic was not the beginning of the RNA story. Instead, it accelerated technologies that had already been under development for years.
Immitra Bio raises CHF 2.4M for in-vivo gene editing
Latest NewsSwiss biotech Immitra Bio has raised CHF 2.4 million (€2.6 million) in pre-seed funding to advance an in-vivo gene editing platform initially targeting inherited blood disorders.
Phinomics Brings a New Layer of Cancer Biology from the U.S. to Berlin
Latest NewsU.S. biotech company Phinomics has established its European hub at Bayer Co.Lab Berlin, bringing a research focus that could reshape how scientists understand tumor evolution and drug resistance. The focus is on extrachromosomal DNA rings.
Samsung Targets Swiss CDMO PolyPeptide in $1.8 Billion Deal
Latest NewsConsolidation in the contract development and manufacturing organization (CDMO) sector continues to accelerate. With a bid valued at approximately US$1.8 billion for Swiss peptide specialist PolyPeptide, Samsung Biologics aims to strengthen its position in the fast-growing market for complex biopharmaceuticals.
Brenus adds €11M to colorectal cancer vaccine development
Latest NewsFrench biotech Brenus Pharma has raised an €11 million Series A extension to complete the Phase 1 development of its lead colorectal cancer immunotherapy and advance a second programme from its platform.
RNA medicine enters its second act
Background, Latest NewsThe COVID-19 pandemic transformed RNA technologies into one of the most visible scientific breakthroughs of the decade. mRNA vaccines demonstrated unprecedented speed of development, large-scale manufacturing capability and global deployment, pushing RNA therapeutics into the public spotlight. But according to companies working in the field, the pandemic was not the beginning of the RNA story. Instead, it accelerated technologies that had already been under development for years.
Sightera raises €3M to advance AI-generated molecular glues
Latest NewsBelgian techbio Sightera Biosciences has raised €3 million in pre-seed financing to expand its AI drug discovery platform and advance a pipeline of small molecules in oncology and fibrosis.
GSK setback deepens P2X3 cough drug doubts
Latest NewsGSK has stopped developing camlipixant for refractory chronic cough after mixed Phase 3 results, adding another setback to a P2X3 drug class that has repeatedly struggled to turn biological promise into convincing clinical benefits.
Stepping up in Innsbruck
AssociationsOn 13–14 October 2026, BIOTECH SUMMIT AUSTRIA brings Europe’s biotech community to Innsbruck for high-level keynotes, policy insights, partnering and networking
in a landmark Alpine setting.
Isomorphic megadeal lifts UK biotech funding to five-year high
Latest NewsUK biotech companies raised £2.11 billion in equity financing in the second quarter of 2026, as a record round for Isomorphic Labs pushed venture investment to its highest level in five years.
Orakl takes on four Sanofi cancer assets
Latest NewsFrench techbio Orakl Oncology has secured exclusive rights to four undisclosed oncology assets from Sanofi, giving the startup an opportunity to test whether its combination of patient-derived tumour models and artificial intelligence can improve drug development decisions.